Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.530
+0.046 (9.49%)
At close: Mar 9, 2026, 4:00 PM EDT
0.525
-0.005 (-0.87%)
After-hours: Mar 9, 2026, 7:24 PM EDT
Longeveron Revenue
Longeveron had revenue of $137.00K in the quarter ending September 30, 2025, a decrease of -82.28%. This brings the company's revenue in the last twelve months to $1.44M, down -22.41% year-over-year. In the year 2024, Longeveron had annual revenue of $2.39M with 237.38% growth.
Revenue (ttm)
$1.44M
Revenue Growth
-22.41%
P/S Ratio
7.86
Revenue / Employee
$57,480
Employees
25
Market Cap
11.30M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLGVN News
- 12 days ago - Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - GlobeNewsWire
- 24 days ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 4 weeks ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire
- 5 weeks ago - Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - GlobeNewsWire
- 2 months ago - Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - GlobeNewsWire
- 3 months ago - Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - GlobeNewsWire
- 3 months ago - Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 3 months ago - Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire